With Thursday approval from the U.S. Food and Drug Administration for Cobenfy, adults living with schizophrenia will have ...
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...
But Cobenfy can still cause side effects, the most common of which are gastrointestinal in nature like nausea and vomiting, diarrhea, indigestion, and constipation. The FDA says people with known ...
The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...